Associated Papers
Performance and considerations in the use of diagnostic mutation panels for clonality testing in non-small-cell lung carcinoma.
Janssen J et al.
Esmo Open, 2025
40373350 (PubMed )
Supplement: mmc4.xlsx › 4c_Correctly_classified
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_3.xlsx › KRAS_G12D_LOF_DMS_Screens
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.
Damianou A et al.
Life Science Alliance, 2024
Development of a high-throughput TR-FRET screening assay for a fast-cycling KRAS mutant.
Larson JE et al.
Slas Discovery : Advancing Life Sciences R & D, 2023
A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions.
Miller SP et al.
Molecular & Cellular Proteomics : Mcp, 2022
35839996 (PubMed )
Supplement: mmc1.pdf
Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
Yelland T et al.
Journal of Medicinal Chemistry, 2022
35104933 (PubMed )
Supplement: jm1c01265_si_001.pdf
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
McFall T et al.
Cell Communication and Signaling : Ccs, 2020
A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.
Fiordalisi JJ et al.
The Journal of Biological Chemistry, 2002
Select a paper to view details